Journal of Cancer Research and Therapeutics Close
 

Figure 3: Q1 aggregate and dead cells, Q2 late apoptotic cells, Q3 live cells, and Q4 early apoptotic cells. (a) Cystic fibrosis pancreatic adenocarcinoma cell line-1 24 h control cells (Q1: 0.5%, Q2: 0.1%, Q3: 99.1%, and Q4: 0.3%). (b) Cells treated with danusertib for 24 h (Q1: 0.4%, Q2: 3.7%, Q3: 81%, and Q4: 14.8%)

Figure 3: Q1 aggregate and dead cells, Q2 late apoptotic cells, Q3 live cells, and Q4 early apoptotic cells. (a) Cystic fibrosis pancreatic adenocarcinoma cell line-1 24 h control cells (Q1: 0.5%, Q2: 0.1%, Q3: 99.1%, and Q4: 0.3%). (b) Cells treated with danusertib for 24 h (Q1: 0.4%, Q2: 3.7%, Q3: 81%, and Q4: 14.8%)